Get the Stockscreener App
27.00
1.89%
-0.52
After Hours:
27.00
Xencor Inc stock is traded at $27.00, with a volume of 1.66M.
It is down -1.89% in the last 24 hours and up +43.54% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$27.52
Open:
$27.01
24h Volume:
1.66M
Relative Volume:
1.66
Market Cap:
$2.01B
Revenue:
$97.36M
Net Income/Loss:
$-172.42M
P/E Ratio:
-11.75
EPS:
-2.2984
Net Cash Flow:
$-188.84M
1W Performance:
+17.44%
1M Performance:
+43.54%
6M Performance:
+136.63%
1Y Performance:
+259.52%
1-Day Range:
$26.52
$27.70
1-Week Range:
$22.50
$27.70
52-Week Range:
$7.13
$27.70
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
27.00 | 2.05B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC - MarketBeat
Xencor stock hits 52-week high at 26.18 USD - Investing.com
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $20 to $44 - Moomoo
Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next? - Kalkine Media
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline? - simplywall.st
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts - simplywall.st
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher - Moomoo
(XNCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Xencor (NASDAQ:XNCR) Hits New 1-Year HighHere's What Happened - MarketBeat
Xencor stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Canada
Xencor stock hits 52-week high at 21.99 USD - Investing.com
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results - webull.com
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit - Yahoo Finance
BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Xencor Inc (XNCR) Stock News Today - TradingKey
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside - TradingView
Xencor, Inc. (XNCR) Stock Report: A Biotech Innovator With 40.83% Upside Potential - DirectorsTalk Interviews
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - theglobeandmail.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Xencor: Q2 Earnings Snapshot - AOL.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $44 - Moomoo
XENCOR Maintains Outperform Rating -- Price Target Raised to $20 - GuruFocus
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Xencor (NASDAQ:XNCR) Surges: What Comes Next? - Kalkine Media
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities? - simplywall.st
Xencor (NASDAQ:XNCR) Price Target Raised to $30.00 - MarketBeat
Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings - marketbeat.com
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating - marketscreener.com
RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald - marketbeat.com
Xencor, Inc. Stock 12‑Month Price Target Raised to $28.5, Implies 44% Upside - TradingView
Xencor Inc (XNCR) SWOT Analysis: Financial Challenges and Strate - GuruFocus
Xencor Inc earnings beat by $0.51, revenue topped estimates - Investing.com
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS - MarketBeat
Xencor, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XENCOR ($XNCR) Releases Q2 2026 Earnings - Quiver Quantitative
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments - TradingView
Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary - TradingView
Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M - Stock Titan
Xencor reports Q2 2026 revenue $51.2M, net loss $21.7M; cash $486.4M - TradingView
Earnings Flash (XNCR) Xencor, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $18.9M - marketscreener.com
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):